Prior to joining TPG Biotech in May 2005, Dr. Preston spent two years at JP Morgan Partners where she focused on medical device and
biotechnology venture capital investing.
Not exact matches
About Pappas
Capital Founded in 1994, Pappas
Capital invests exclusively in the life sciences sector —
biotechnology, biopharmaceuticals, drug delivery, medical devices and related
ventures — across the United States and Canada.
HealthEquity is a Spanish
venture capital firm
investing in early - stage companies in the healthcare sector, with a special focus on
biotechnology, medical devices and healthcare services.
The National
Venture Capital Association has reported that, in 2014, venture capital investment in the life sciences was at its highest level since 2008: in biotechnology, $ 6.0 billion was invested in 470 deals and, in life sciences overall, $ 8.6 billion in 789 deals (including biotechnology and medical de
Venture Capital Association has reported that, in 2014, venture capital investment in the life sciences was at its highest level since 2008: in biotechnology, $ 6.0 billion was invested in 470 deals and, in life sciences overall, $ 8.6 billion in 789 deals (including biotechnology and medical de
Capital Association has reported that, in 2014,
venture capital investment in the life sciences was at its highest level since 2008: in biotechnology, $ 6.0 billion was invested in 470 deals and, in life sciences overall, $ 8.6 billion in 789 deals (including biotechnology and medical de
venture capital investment in the life sciences was at its highest level since 2008: in biotechnology, $ 6.0 billion was invested in 470 deals and, in life sciences overall, $ 8.6 billion in 789 deals (including biotechnology and medical de
capital investment in the life sciences was at its highest level since 2008: in
biotechnology, $ 6.0 billion was
invested in 470 deals and, in life sciences overall, $ 8.6 billion in 789 deals (including
biotechnology and medical devices).
According to Heathers,
venture capital businesses with an interest to
invest in the
biotechnology industry will benefit by having scientists on their teams.
Venture capital organisations in Europe invested # 62 million in biotechnology in 1991, down from # 101 million in 1989, according to figures published last week by the European Venture Capital Association and KPMG, the management consultanc
capital organisations in Europe
invested # 62 million in
biotechnology in 1991, down from # 101 million in 1989, according to figures published last week by the European
Venture Capital Association and KPMG, the management consultanc
Capital Association and KPMG, the management consultancy firm.
Here's $ 100 million that is definitely going to
biotechnology: Texas announced $ 50 million of funding for a National Center for Therapeutics Manufacturing, but can't shake anti-stem cell legislators or a creationist curriculum, and Merck KGaA is starting a
biotechnology venture capital fund that will
invest $ 40 million in emerging biotech companies during the next five years.